SUBSEQUENT EVENTS	9 Months Ended
Sep. 30, 2011
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	(14) SUBSEQUENT EVENT On October 27, 2011, the Company entered into an agreement with Platinum Long Term Growth VII, LLC (“Platinum”) and Platinum Montaur Life Sciences, LLC (“Montaur”) pursuant to which Platinum and Montaur exercised certain warrants to purchase Common Stock and, in lieu of delivering the cash exercise price for such warrant exercises, Montaur, on behalf of itself and Platinum, surrendered an aggregate of 170.1672 shares of the Series B Stock held by it, with a redemption value of $1,701,672, as full payment for the exercise of the warrants (the “Exchange”). After giving effect to the Exchange, the Company has no issued or outstanding Series B Stock. As part of the Exchange, Platinum exercised its warrants in full and Montaur exercised certain of its warrants in full and certain of its warrants in part. In the aggregate, and without giving effect to any beneficial ownership limitation provisions contained in the warrants, the warrant exercises would have resulted in the issuance to Platinum and Montaur of 1,830,895 shares of Common Stock. In connection with the Exchange, the Company agreed that the exercise price for Montaur's Series 2 warrants issued in February 2011 to be exercised as part of the Exchange (and only such February 2011 Series 2 warrants) would be reduced from $2.50 per share to $1.50 per share for purposes of the Exchange. As part of the Exchange, Platinum and Montaur requested, and the Company agreed, that the Company would, in lieu of issuing 1,830,895 shares of Common Stock, issue an aggregate of 1,830.895 shares of Series C Stock to Montaur. After the Exchange, Montaur holds no shares of Series B Stock and 6,749.001 shares of Series C Stock.

(14) SUBSEQUENT EVENT

On October 27, 2011, the Company entered into an agreement with Platinum Long Term Growth VII, LLC (“Platinum”) and Platinum Montaur Life Sciences, LLC (“Montaur”) pursuant to which Platinum and Montaur exercised certain warrants to purchase Common Stock and, in lieu of delivering the cash exercise price for such warrant exercises, Montaur, on behalf of itself and Platinum, surrendered an aggregate of 170.1672 shares of the Series B Stock held by it, with a redemption value of $1,701,672, as full payment for the exercise of the warrants (the “Exchange”). After giving effect to the Exchange, the Company has no issued or outstanding Series B Stock.

As part of the Exchange, Platinum exercised its warrants in full and Montaur exercised certain of its warrants in full and certain of its warrants in part. In the aggregate, and without giving effect to any beneficial ownership limitation provisions contained in the warrants, the warrant exercises would have resulted in the issuance to Platinum and Montaur of 1,830,895 shares of Common Stock.

In connection with the Exchange, the Company agreed that the exercise price for Montaur's Series 2 warrants issued in February 2011 to be exercised as part of the Exchange (and only such February 2011 Series 2 warrants) would be reduced from $2.50 per share to $1.50 per share for purposes of the Exchange.

As part of the Exchange, Platinum and Montaur requested, and the Company agreed, that the Company would, in lieu of issuing 1,830,895 shares of Common Stock, issue an aggregate of 1,830.895 shares of Series C Stock to Montaur.

After the Exchange, Montaur holds no shares of Series B Stock and 6,749.001 shares of Series C Stock.